House of Commons
EDM #1879
Tabled 27 November 2018
2017-19 Session
That this House notes that in the event of a no-deal Brexit, the Government has stated that companies may need to stockpile medicines, including essential drugs for the treatment of diabetes and other chronic, life threatening conditions; further notes the comments made by Mike Thompson, Chief Executive of the Association of the British Pharmaceutical Industry where he said, stockpiling by industry won’t be enough, as well as the comments by Professor Sir Michael Rawlins, Chair of the Medicines and Healthcare Products Regulatory Agency, that disruption to the insulin supply chain is one of the ways that patients could be severely disadvantaged by Brexit; expresses concern that Brexit may threaten access to essential drugs required to manage and treat a wide range of diseases and conditions; and calls on the Government to provide reassurance to people with drug dependent illnesses regarding their access to essential drugs if a no-deal Brexit is the outcome of negotiations.